Unlike tocilizumab, etanercept slightly increases experimental thrombin-induced aggregation in healthy individuals.
Établissement français du sang Rhône-Alpes-Auvergne, 42100 Saint-Étienne, France; EA3064-GIMAP, université de Lyon, 42023 Saint-Étienne, France. Electronic address: fabrice.cognasse@univ-st-etienne.fr.
Fabrice
F
Cognasse
EA3064-GIMAP, université de Lyon, 42023 Saint-Étienne, France; INTS - institut national de la transfusion sanguine, 75015 Paris, France.
Olivier
O
Garraud
Research Unit U1059, institut national de la santé et de la recherche médicale, université de Lyon, 42023 Saint-Étienne, France; Department of Rheumatology, CHU de Saint-Étienne, 42055 Saint-Étienne, France.
Hubert
H
Marotte
D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D000068800:Etanercept / Q000494:pharmacology*; D064368:Healthy Volunteers; D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects*; D053657:Platelet-Rich Plasma; D012680:Sensitivity and Specificity; D013917:Thrombin / Q000187:drug effects*
D061067:Antibodies, Monoclonal, Humanized; D013917:Thrombin; C502936:tocilizumab; D000068800:Etanercept
Etanercept; Inflammation; Platelet; Rheumatoid arthritis; Tocilizumab